Eine wichtige Quelle für Optimismus in der Myelom-Gemeinschaft ist heutzutage die große Anzahl potenziell sehr effektiver Behandlungen, die sich in der Entwicklung befinden.

Eine steigende Anzahl wirksamer Behandlungsmöglichkeiten für die Erkrankung könnte zu einem erheblichen Anstieg der Überlebensraten sowohl bei neu diagnostizierten als auch bei rezidivierten Patienten mit multiplem Myelom führen.

Es gibt jedoch ein gemeinsames Thema unter vielen der vielversprechenden Forschungstherapien für das multiple Myelom, das den Einfluss dieser Therapien auf das Myelomüberleben (wie viele hoffen) einschränken könnte. Das gemeinsame Thema lässt sich in vier Buchstaben zusammenfassen: BCMA.

BCMA, oder B-Zell-Reifungsantigen, …

A major source of op­ti­mism in the myeloma com­munity these days is the large num­ber of poten­tially very ef­fec­tive treat­ments under devel­op­ment for the dis­ease.

Increasing the num­ber of ef­fec­tive treat­ment op­tions for the dis­ease could lead to a sizable jump in sur­vival for both newly diag­nosed and re­lapsed mul­ti­ple myeloma patients.

There is, how­ever, a common theme among many of the promising inves­ti­ga­tional ther­a­pies for mul­ti­ple myeloma that could limit their ability to make as large an im­pact on myeloma sur­vival as many hope. The common theme can be summarized in …

San Diego, CA (Press Release) – Poseida Therapeutics Inc., a clin­i­cal-stage bio­pharma­ceu­tical com­pany leveraging pro­pri­e­tary non-viral gene engi­neer­ing tech­nolo­gies to create life-saving thera­peutics, today announced the United States Food and Drug Admin­istra­tion (FDA) has granted orphan drug desig­na­tion to P-BCMA-101 for the treat­ment of re­lapsed and/or refractory multiple myeloma. P-BCMA-101 is an au­tol­o­gous CAR-T ther­apy devel­oped using Poseida’s piggyBac® plat­form tech­nology. P-BCMA-101 is com­prised of a high per­cent­age of long-lived, self-renewing stem cell memory T cells targeting cancer cells expressing B-cell maturation an­ti­gen (BCMA).

“FDA orphan desig­na­tion is an im­por­tant regu­la­tory mile­stone in …

San Diego, CA (Press Release) – Poseida Therapeutics Inc., a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on leveraging pro­pri­e­tary next-generation, non-viral gene engi­neer­ing tech­nolo­gies to create life-saving thera­peutics, today announced the U.S. Food and Drug Admin­istra­tion (FDA) has granted a Regenerative Medicine Advanced Therapy (RMAT) desig­na­tion to P-BCMA-101, Poseida’s lead CAR-T thera­peutic can­di­date cur­rently in a Phase 1 clin­i­cal trial for the treat­ment of patients with re­lapsed / refractory multiple myeloma. RMAT desig­na­tion in­cludes all of the benefits of the Fast Track and Break­through Therapy desig­na­tion pro­grams, in­­clud­ing early inter­actions with the FDA.

“P-BCMA-101 is the …

• Efficacy and safety con­tinue to be a major ad­van­tage, with a very high response rate, no dose limiting toxicities and only a single in­ci­dence of sus­pected cytokine release syn­drome
• P-BCMA-101 clin­i­cal data as well as pre­clin­i­cal data from MUC1C and PSMA solid tumor pro­grams and BCMA allo­geneic pro­gram presented at the CAR-TCR Summit

San Diego, CA (Press Release) – Poseida Therapeutics Inc. (“Poseida”), a clin­i­cal-stage bio­tech­nology com­pany translating best-in-class gene engi­neer­ing tech­nolo­gies into lifesaving cell ther­a­pies, announced data results from the first eleven patients treated in its ongoing Phase 1 study of its P-BCMA-101 stem cell memory chi­meric an­ti­gen re­cep­tor T-cell (CAR-T) prod­uct in re­lapsed / refractory multiple myeloma. All eleven patients remain on study with seven of ten patients evaluable by Inter­na­tional Myeloma Work­ing Group (IMWG) criteria achieving at least a partial response. The remaining patient also dem­onstrated …